La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Senti Biosciences Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Senti Biosciences ha un patrimonio netto totale di $56.1M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $102.2M e $46.1M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$15.95m
Patrimonio netto	US$44.15m
Totale passività	US$42.77m
Totale attività	US$86.91m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Dec 28

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Sep 27

Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform

Sep 22

Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M

Aug 16

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Jun 13

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $55.7M ) di SNTI superano le sue passività a breve termine ( $9.6M ).

Passività a lungo termine: Le attività a breve termine di SNTI ( $55.7M ) superano le sue passività a lungo termine ( $36.5M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: SNTI è esente da debiti.

Riduzione del debito: SNTI non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: SNTI ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: SNTI ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 25 % ogni anno

Senti Biosciences Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Nasdaq Grants Senti Biosciences’ Request to Transfer the Listing of its Common Stock from The Nasdaq Global Market Tier to The Nasdaq Capital Market Tier, Effective January 25, 2024

Senti Biosciences Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Senti Biosciences Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Recent updates

Senti Biosciences, Inc. Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Senti Biosciences, Inc., Annual General Meeting, Jul 10, 2024

Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024

Nasdaq Grants Senti Biosciences’ Request to Transfer the Listing of its Common Stock from The Nasdaq Global Market Tier to The Nasdaq Capital Market Tier, Effective January 25, 2024

Spark Therapeutics, Inc. Announces Workforce Reduction

Spark Therapeutics, Inc. Announces Workforce Reduction

Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Senti Biosciences Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Senti Biosciences Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Senti Biosciences, Inc. Announces Resignation of Philip Lee as Chief Technology Officer

New minor risk - Share price stability

Senti Biosciences, Inc. Highlights Initial Gene Circuit Data from Collaborations At the American Society of Gene and Cell Therapy Annual Meeting

Consensus EPS estimates upgraded to US$1.54 loss

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.92 loss

Senti Biosciences, Inc. Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Senti Biosciences, Inc. Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform

Second quarter 2022 earnings released

Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M

Senti Biosciences, Inc. Announces Resignation of Curt A. Herberts III, Chief Operating Officer Effective as of August 19, 2022

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Senti Biosciences, Inc. Announces Board Appointments

Less than half of directors are independent

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane